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Abstract
Background and Purpose. This study analyses the dosimetric and dose averaged Linear Energy 
transfer (LETd) correlation in paediatric craniopharyngioma (CP) patients with and without 
radiation-induced cerebral vasculopathies (RICVs) treated with pencil beam scanning (PBS) 
proton therapy (PT). 
Material and Methods. We reviewed a series of 16 CP patients treated with PT to a median 
dose of 54 Gy(RBE). Two (12.5%) index patients presented RICVs 14 and 24 months (median, 
19) after PT. Organs at risks (OARs) as bilateral internal carotid arteries (ICAs) and circle of 
Willis were contoured based on CTs and MRIs pre- and post-PT. Dosimetry was reviewed and 
LETd distributions were calculated; LETd metric for PTVs and OARs were analysed. For a sub-
cohort, dosimetric and LETd values robustness due to range uncertainties were computed. 
Results. 
For the two index patients, no correlation was observed between RICVs and OARs doses. 
However for those patients mean(maximum) LETd values in the affected OARs were up to 
4.0±0.4 (7.8±0.1)keV/m; those LETd values were significantly higher (p=0.02) than the 
mean(maximum) LETd values for the rest of the cohort (mean: 3.1±0.3, maximum: 
4.8±1.0keV/m). This was due to asymmetric field arrangement, thus resulting in marked 
asymmetric LETd distributions. For such arrangement, maximum LETd values variations in 
vascular structures due to range uncertainties were up to 1.2keV/m, whilst for the 
symmetric one they were up to 0.7keV/m.
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Conclusions. For children with and without RICVs, quantitative analysis showed a significant 
correlation with LETd average/maximum values in vascular structures, whilst no correlation 
was found on dosimetric parameters. 
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Introduction 
Radiation-induced cerebral vasculopathy (RICV) has been described in paediatric patients 
after radiation therapy (RT) for tumours of optic tracts, hypothalamus, and suprasellar region 
[1, 2]. Delayed RICV mainly results from an accelerated arteriosclerosis process of small and 
medium sized vessels within the radiation field [3, 4]. This complication can present as 
moyamoya syndrome, which results from stenosis or occlusion of large and intermediate 
cerebral arteries [5]. The real incidence of RT-induced stenosis of carotid arteries and 
intracerebral arteries is however not well established. It seems that the vasculature of young 
children, when compared to adult patients, is more radio-sensitive to vasculature damage.  In 
one report, moyamoya syndrome after RT has been observed most commonly in children <5 
years of age receiving RT to the suprasellar region [6]. The Circle of Willis is often located in 
high dose region (≥ 45Gy) in the irradiation of suprasellar tumors; however the development 
of moyamoya syndrome seems to be independent from the radiation delivered to vascular 
structure and may result from pre-irradiation compressive vasculopathy and manipulation of 
vessels during surgeries [6, 7]. Craniopharyngiomas (CPs) are rare epithelial tumours arising 
along the path of the craniopharyngeal duct located in the suprasellar region. Despite their 
non-infiltrative growth pattern, their adherence/compression to nearby critical organs at risk 
(OARs) makes the treatment challenging. As such, radiation-induced complications, including 
but not limited to pituitary dysfunction, cognitive deficits, visual impairment and brain 
necrosis have been reported. Importantly, late effects on the vasculature, such as cavernomas 
or hemangiomas [8, 9], has been observed not infrequently. The superior dose profile and 
distribution provided by proton therapy (PT) may contribute to a reduced exposure of normal 
tissue, including blood vessels.  The relative biological effectiveness of protons (RBE), 
approximated to be constant and equal to 1.1. RBE, depends however on physical properties, 
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such as the Linear Energy Transfer (LET) and dose per fraction, as well as biological properties 
including cell type and clinical endpoint. Moreover, LET and consequently  RBE value increases 
at the end of the proton beam range [10]: this could translate into a potential increase of 
toxicity of normal tissue within and immediately adjacent to the region of elevated RBE-
weighted dose. 
In this study, we propose a) to report two cases of RICV after PBS PT for pediatric CP patients, 
b) to assess the dosimetry of plans delivered to CP patients with or without RICV and c) to 
evaluate dose-averaged linear energy transfer (LETd) distributions for all the patients and its 
intrinsic uncertainty with special focus on these RICVs.
Materials and Methods 
Patients’ cohort and clinical outcome 
Sixteen paediatric patients treated for CP with PBS PT from 2008 to 2014 with >1 year of 
follow-up were identified from the Paul Scherrer Institute’s  institutional database. Median 
age was 9.5 years (range, 2.0 – 18.2), 63% of the patients were female. Thirteen (81%) patients 
had hypopituitarism and 12 (75%) had a visual defect prior to PT, respectively. PT was 
administered for progressive disease after surgical resection (n=13; 81%) or postoperatively 
after partial resection (n=3; 19%). Median time from diagnosis to delivery of PT ranged from 
4.0 months to 8.8 years (median, 13.0 months). A dose of 54.0 Gy Relative Biological 
Equivalent (Gy(RBE)) was delivered at 1.8 Gy(RBE) per fraction, five times per week. The 
planning- (PTV) and clinical- (CTV) target volume median values were 43.0 cm3 (range 11.6-
159.8) and 24.4 cm3 (range 5.8-88.5) respectively. PTV was generated as a 5 mm isotropic CTV 
expansion.
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Institutional review board-approval was obtained to analyse retrospectively the treatment-
related toxicity of PT of these patients (EKNZ 2015-423).  
Two out of 16 patients (12.5%), showed RICV 1.2 and 2 years after PT (indicated as index 
patients). One 5-year-old patient with toxicity, (patient A), received PT 7 months after the 
initial diagnosis and multiple cyst aspirations in two surgical procedures. Two years after 
irradiation, she developed several transient ischaemic attacks (TIAs) with a right facial paresis. 
The MRI revealed a small mid-left infarct and progressive multifocal RICVs in the region of the 
circle of Willis (Fig. 1b). She is currently taking aspirin for anticoagulation.  The other index 
patient was an 8.6-year-old girl (patient B), who underwent subtotal transphenoidal resection 
followed by adjuvant PT, 5 months after initial diagnosis. MR imaging 14 months after 
irradiation revealed a stenosis of right internal carotid artery (Fig. 1d). The patient was 
however asymptomatic. 
Dosimetric analysis and LETd distribution
Planning CT and MRI pre- (n=16) and post- treatment (MRI TOF 3D, mprage T1, T2) images 
[11], were used to contour the clinical volume of interest, as the OARs for vascular toxicity and 
PT target volumes. OARs were delineated by a senior radiation oncologist (AP) and neuro-
oncologist (FA), and consisted of the circle of Willis’ structures with internal carotid arteries 
and basilar artery. A detailed dosimetric analysis was performed and dose metrics as mean 
and maximum dose (for OARs) and V95% (the volume receiving at least 95% of the prescribed 
dose) for PTV were computed from the dose volume histograms (DVHs). 
LETd distributions were computed according to Wilkens and Oelfke [12] (Appendix A) and 
LETd metrics (mean and maximum) for the PTV and OARs were analysed. In our 
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implementation, 1D LETd calculations are performed in water, considering only primary 
protons. Mean and maximum LETd values were calculated for all voxels within each ROI.  
Range uncertainties and consequences on dose and LETd distributions
High LETd values are linked to high biological effectiveness for proton fields, especially at the 
end of range [10, 13] therefore small range uncertainties should be taken into account when 
evaluating dose distributions [14-16]. Considering the small OARs size and the dose/LETd 
gradients close to those structures, range uncertainties could significantly affect both dose 
and LETd values.  
 Image guidance was based on 2D-daily topograms acquired on the CT located in treatment 
room and compared with reference topograms acquired with the planning CT. Bite 
immobilisation was used for 31% of the patients’ cohort, resulting in systematic and random 
positioning errors within 0.16 mm and 1.22 mm respectively. Five patients received 
anaesthesia during the treatment, thus further minimising intrafractional positioning 
uncertainties. Therefore, for this population, CT calibration uncertainties represent the main 
contribution to range uncertainties [15, 17]. This effect was simulated for a sub-cohort of 
patients representative of different field arrangements, including the two index cases, by 
introducing a +/-3% HU variation on the nominal planning CT [18] and recalculating the 
nominal dose. As the maximum depths of those tumours was 10.8±1.7 cm (range 7.8-13.4 
cm), this translated in range errors of 0.32±0.05 cm. Additionally, based on the recalculated 
dose distributions, the nominal LETd distributions (LETdN) were recomputed, thus obtaining 
new LETd distributions with simulated range error (LETdRE). Nominal doses and LETd metrics 
were compared to the values obtained assuming ± 3% HU variations.
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Dose–volume parameters derived from dose and LETd distributions were evaluated with the 
Kruskal-Wallis non-parametric test, to compare the results for the index patients vs the non-
RICVs ones. A p-value <0.05 considered statistically significant.
Results 
After 9.5 months’ follow up (range: 14.0-75.0), tumours’ volume decreased for 3 (18.8%) 
patients and remained stable for 13 (81.2%) other patients. No tumor progression or other 
non-vascular toxicities were observed during the follow-up. One patient with visual defect 
prior to PT had improved visual function post-treatment, whereas three patients with partial 
visual defects prior to PT had functional decline. The estimated 3-year vision preservation rate 
was 92.8%. The 3-year survival without new anterior pituitary deficit was 77.3%.
For our patient cohort, the prescribed dose of 54 Gy(RBE) did not exceed tolerance doses for 
the optical structures or brainstem,  therefore Single Field Uniform Dose (SFUD) technique 
was used for 13/16 patients (81%), whilst for the remaining three patients (19%) Intensity 
Modulated Proton Therapy (IMPT) technique was applied [19].  Multiple fields plans (range: 
2-4) with either symmetric (S, including at least one contralateral field) or asymmetric (A, no 
contralateral fields) were used for all the cases.  In this cohort, three (19%) had asymmetric 
fields, of which two (67%) presented with RICVs. 
Quantitative dosimetric results, based on the DVH metrics for PTV and OARs, did not reveal 
any evident dose metric/toxicity correlation (Table1). 
For OARs, often located in high dose gradients, average dose values, were analysed and 
reported. No significant differences between the index cases and the non-RICV patients were 
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found for either mean OAR dose or  PTV size. The largest PTV volume was however found for 
one of the index patients. Target coverage (V95% in PTV) was  comparable among all patients. 
The results of the LETd metric analysis for PTV and OARs are shown in Table 2, where p-values 
are reported concerning the differences of (i) index cases vs. non-RICV patients and (ii) 
asymmetric vs symmetric field arrangements. 
Maximum LETd values for vascular structures are up to 7.9 keV/µm (vasculature left, patient 
A) and 7.7 keV/µm (vasculature right, patient B), who both presented with toxicity on the left 
and right side respectively. These values (see Fig. 2a), as well as the average LETd in the OAR, 
and maximum LETd in the PTV, were significantly higher than the ones for the rest of the 
population. As reported in Fig 2b and Fig 2c, for the index cases, the high maximum/mean 
LETd values are combined with high mean dose values in the vascular structures. Two non-
RICV patients (pt C and D) presented with maximum LETd values > 5.5 keV/µm in the vascular 
structures, but with mean dose well below prescription (<45 Gy(RBE)). Finally, figure 2c shows 
that, although the combination of mean dose and mean LETd separate the index cases from 
the rest, the separation is not a clearly defined as for the combination of mean dose and 
maximum LETd. 
The three patients treated with asymmetric fields had significantly higher (p<0.002, p<0.01) 
maximum LETd values in the PTV and OARs, compared to patients treated with symmetric 
fields (Fig. 2, Table2). For one of these patients (patient D), OAR maximum LETd was  above 
7keV/µm,  thus comparable to index patients’  values, but had a mean dose < 42Gy(RBE). 
For asymmetric plans the high LETd area is also localized asymmetrically at the distal range of 
the lateral fields, involving the side of the Willis’ structure with toxicity. For symmetric plans 
instead, high LETd areas are localized anteriorly and posteriorly outside the PTV (Fig. 3).
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The effect of range uncertainties in mean dose and in maximum LETd values to OARs (ΔLETd 
between LETdN and LETdRE metric values), are shown in Supplemental Table 1 for 4 patients 
who were selected as representative of the asymmetric (patient A and B) and symmetric 
(patient C and E) approaches. The OAR mean dose differences , due to 3% HU variations, are 
slightly higher for the index patients as compared to the non-RICVs patients. Nevertheless, 
the maximum estimated increase of the OARs mean dose for the index patients would result 
in values well within the average. 
The differences due to 3% HU variation in maximum OARs LETd are up to 1.2keV/m (15%) 
for asymmetric arrangement, and only up to 0.7keV/m (12%) for the symmetric one.  
Additionally, even assuming a decreased LETdRE in the OARs for the index patients 
(Supplemental Table1) the difference between maximum LETd values for index cases vs non-
RICV patients would still be significant (p=0.02). LETdN and LETdRE distributions for the four 
patients included in the LETd range uncertainty analysis are depicted in Fig. 4. 
Discussion
In this study we investigated dose and LETd distributions for 16 CP patients treated with 
proton PBS at PSI, between 2008 and 2014. Two of them (12.5%), showed RICVs 1.2 and 2 
years after PT. Wang et al reviewed reported 77 cases of delayed RICV. The median interval 
period for moyamoya cases was 3.3 years (range 0.3-20, p<0.001) with photons [20].  The 
circle of Willis is a critical organ at risk for cerebral vascular accidents (CVA) after cranial RT. 
With a median follow up of 26 years, relative risk of CVA was 15.7% with ≥ 40 Gy(RBE) to the 
circle of Willis [21]. Large vessel cerebral vasculopathy after PT in paediatric patients seems 
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to occur earlier according the literature. Kralik et al [22] reported the median time from 
completion of RT to development was 1.5 years (mean, 3.0 years; range, 1.0-7.5 years). Hall 
et al [23] found in 644 pediatric patients, with a median follow up of 3.0 years (range, 0.1-9.6 
years), a 3-years cumulative rate of serious vasculopathy of 2.6%. In this study major vessels 
were specifically contoured as OARs. In our analysis, no correlation was observed between 
dose distributions in the vascular structures and toxicity, therefore the analysis was extended 
to LETd distributions (maximum and mean values). For this, we have used maximum LETd as 
a metric.  Although this strongly depends on the calculation grid, the use of more common 
surrogates of maximum dose, such as D2 would have a similar problem, due to the small OAR 
volume where 1 voxel equals about 1% of the volume.  
In our analysis patients with RICVs (patient A and B), present with the highest maximum LETd 
values in the PTV (Table 2) (> 5.5keV/µm). Moreover, they also have the highest maximum 
LETd value, of 7.9keV/µm (vasculature left) and 7.7keV/µm (vasculature right), respectively, 
in the anatomical area of the observed toxicity. These values are larger than the average of 
the maximum LETd values for the non- RICV patients (7.8keV/µm and 4.8keV/µm 
respectively). Nevertheless, two non-RICV patients presented with LETd values > 7 keV/µm 
(ptD) and 5.5 keV/µm (ptC) in the vascular structures. As shown in Figure2b the index patients 
presented with the combination of both high maximum LETd and mean dose in the vascular 
structures (maximum LETd>7 keV/µm and mean dose>45 Gy(RBE)). One explanation of this 
could be that the ‘circle of Willis’ has a strong volume effect, meaning that its tolerance to 
localized high LETd regions is compromised (lowered) when a large volume of the structure is 
irradiated, even if high LETd region does not correspond to high dose region.
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Similar LETd evaluation have been performed previously by Giantsoudi et al. [24], who 
reviewed 111 consecutive patients treated with PT for medulloblastoma between 2002 and 
2011 including 10 selected patients with clinical symptoms of CNS injury. No correlation was 
found between the sites of injury and elevated RBE.
Sethi et al. [25] also evaluated 109 medulloblastoma patients treated with PT, aiming at 
correlating lower LETd values with recurrences. Eleven patients (10%) experienced relapse 
isolated to a single compartment, but no correlation was found between LETd distribution 
and region of recurrence.  
An important limitation of our study is the availability of MR imaging data to accurately 
contour the circle of Willis structures. Ideally, the most adequate pre- and post-treatment 
MRI sequence for contouring such structures is an axial 3D time of flight [26], available only 
for a few (n=2) patients. 
 Target volumes were delineated using CT images co-registrated with T1- and T2- weighted 
post-contrast thin-sliced (1 to 1.5mm slice thickness) MRI.  The GTV included solid and cystic 
components and has historically been expanded by a 10 mm margin to create the CTV.  
Recently, we used a 5 mm CTV margin adapted to anatomical barriers according to the recent 
phase II protocol which prospectively evaluated a 5mm CTV margin using PT with promising 
results in term of disease control and reduced toxicity [27].
The LETd model that was used in this study (unrestricted 1D LETd to water considering primary 
protons only) neglected the contribution of the secondary protons. As described in [28], the main 
contribution of those secondary protons is in the penumbra of the plateau region, decreasing toward 
the peak of the dose distribution. Therefore, their contribution at the end of the range would have 
only limited influence on OAR maximum LETd.
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For this analysis RBE-weighted dose would be the appropriate parameter to describe the 
effect of dose and its radio-biological effect but, due to the complexity of RBE problem, there 
is no clinically validated reliable RBE model to be used [29]. Considering this, Unkelbach et al. 
in 2016 [30] introduced the use of a combined parameter defined as LETxD (product of LETd 
and physical dose), with the main purpose of including the increase of biological dose caused 
by high LETd in the dose optimisation. As this quantity is not yet validated, we have here 
instead evaluated physical doses and LETd distributions as two separate parameters.
Treatment approach (A or S) influences maximum LETd values in the vascular structures; this 
is instead not the case for IMPT vs SFUD. The highest LETd maximum values are for three 
patients (A, B, and D; Table 2) all treated with asymmetric arrangement. Patient D is even 
more an outlier as it presents with high maximum LETd values (>7 keV/µm) in both vascular 
structures (Fig. B1). This result can be interpreted as an indication to use symmetric fields, 
even if asymmetric fields can reduce the dose bath in the contralateral brain. However, it is 
dosimetrically less robust than the symmetric one, and may deliver higher LETd radiation. This 
has been confirmed by the LETd robustness analysis on selected cases with variations of 
maximum LETd below 0.7 keV/µm in case of symmetric, as compared to values below 1.2 
keV/µm in case of asymmetric arrangement. 
No clear correlation was found between toxicity and high maximum LETd of the basilar artery 
(not reported).
In summary, our dosimetric analysis could not objectivize a correlation between dose and 
RICV, whilst the combination of high maximum/average LETd values in the vascular structures 
and high mean dose seems to correlate with RICVs. Of note, both index cases had large PTVs. 
Asymmetric fields were associated with high LETd values, and two of the three patients 
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treated with this arrangement presented with RICVs, as opposed to none of those treated 
with symmetrical fields. As such, we are currently treating all CP patients with a symmetrical 
beam arrangement to potentially limit the likelihood to induce a RICV. This comes however 
at the cost of an increased integral brain dose and future prospective studies, including neuro-
cognitive testing, should better define the optimal therapeutic ration of using asymmetrical 
vs. symmetrical field arrangement for CP patients.
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Fig. 1.  Multifocal vasculopathy in the region of the circle of Willis (yellow arrows). (a) Coronal 
Maximum Intensity Projection (MIP) angiogram of the index patient A 24 months after PT; (b) 
T1-weighted MPRAGE sagittal image showing bright signal intensity (red arrowhead) with a 
cystic component  in the  suprasellar region. (c) Stenosis of the right internal carotid (arrow) 
for index patient B visible on the Coronal Maximum Intensity Projection (MIP) angiogram 14 
months after PT.(d) T1-weighted MPRAGE coronal image showing bright signal intensity 
(arrowhead) in the right suprasellar region
Fig. 2. a) Maximum LETd values for the vascular structures right and left for all the patients. 
In red the values for the structures presenting with toxicity. The continuous lines represent 
the average of the maximum LETd values for vascular structures presenting with toxicities (pt 
A-left and pt B right) and for the rest of the population (shadow area is the standard 
deviation). The first three patients (A, B and D) are the ones with asymmetric field 
arrangements. b) Maximum LETd values vs mean dose  for the vascular structures right and 
left for all the patients. In red the values for the structures presenting with toxicity. Toxicities 
present with both the highest mean doses and maximum LETd values. For the patient D, the 
third one with asymmetric field arrangement, high maximum LETd values are combined with 
mean doses in the vascular structures <42 Gy(RBE). c) Mean LETd values vs mean dose for the 
vascular structures right and left for all the patients. In red the values for the structures 
presenting with toxicity. Toxicities present with both the highest mean doses and mean LETd 
values (>48 Gy(RBE)). For the patient D, the third one with asymmetric field arrangement, 
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only one vascular structure present with mean LETd > 3.5 keV/m , but the mean doses in the 
vascular structures are <42 Gy(RBE).
Fig. 3. Dose distribution and LETd distributions for patient A, C and E. Patient A has a 3  -non 
contralateral fields arrangement while patient C and E have a 2- contralateral fields 
arrangement respectively (Yellow arrows indicate field directions,  if dotted they indicate non 
coplanar fields). High LETd areas are located close to the circle of Willis ‘structures only for the  
non contralateral fields arrangement. The contour for the vascular structures of the circle of Willis 
are shown in green (arrow). For patient A T1-weighted MPRAGE axial image showing a vasculopathy 
in the region of the circle of Willis (green arrow). 
Fig 4. – LETd N and the LETd RE distribution for patient A, B, C and E (from left to tight). In the 
central line are shown the nominal LETd distributions on the planning CTs. On the top the LETd 
RE distributions on the CTs with a HU increases of 3%. On the bottom the LETd RE distributions 
on the CTs with a HU decreases of 3%. PTV is highlighted in yellow, the circle of Willis’ 
structures in green. 
Fig B1 – Patient A (left) and D (right). The shape of the vasculature (highlighted in green), in 
case of the patient D explains how the LETd is high in the left vascular structure (right on the 
screen) despite the asymmetric field arrangement.
Table 1. Field arrangement, number of fields and dose metrics (V95% of the PTV, mean dose 
(%) to Circle of Willis structures) for all the patients included in the study. The values for RICV 
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patients are in italic. No significant differences are found for those parameters between index 
patients and rest of the cohort.
Table 2. Maximum and mean values of dose average LET (LETd) for PTV and vascular structures 
for all the 16 patients. P-values of the differences are reported considering: (i) patients with 
toxicity vs the rest of the cohort; (ii) patients treated with asymmetric (A) field arrangement 
vs patients treated with symmetric field arrangement (S) (in bold and red the significant 
differences). The values for RICV patients are in italic.
Supplemental Table 1. Dosimetric robustness of mean dose to OARs and LETd robustness of 
max LETd values to OARs. Those values are calculated modifying the HU values of the planning 








Patient # Fields’ 
arrangement





volume Vascular R Vascular L Basilar art.






 A-TOX  A 3 92.7 62.4 78.2 91.3* 61.4
 B-TOX  A 3 95.7 159.81 88.7* 90.9 100
C  S 3 92.0 24.81 65.9 64.4 69.9
 D  A 3 92.7 36.98 74.9 75.6 100.1
 E  S 2 93.4 105.7 92.8 94.3 94.6
 F  S 4 92.1 110.69 94.7 97.6 80.1
 G  S 2 93.2 44.35 92.2 91 49.8
 H  S 3 93.3 41.74 82.8 86.3 44.6
 I  S 2 94.4 36.7 88.9 89.6 91.4
 L  S 2 90.5 32.1 85.5 95.7 64.5
 M  S 2 94.7 37.54 92.2 80.1 95.3
 N  S 3 92.1 69.69 97.5 96.4 97.5
 O  S 2 94.8 18.84 67.8 68.1 76.9
 P  S 2 95.5 52.45 85.2 95.4 99.3
 Q  S 3 93.6 105.18 98.6 99 93.5
 R  S 2 89.9 11.63 69.4 81.5 90.2
Fields’ PTV PTV Vascular structures Basilar art.
number V95(%) (cm3)  (mean, %) (mean,%)
mean ± SD 2.6±0.6 93±1.6 59±41 85±15 82±19
mean (RICV) ± SD 3 94±2.2 111±69 87±15 81±27
mean (non RICV) ± SD 2.5±0.6 93±1.7 52±42 86±6 82±18
p value 0.38 0.11 0.88 0.88
mean (A) ± SD 3 94±1.8 86±64 83±8 87±22
mean (S) ± SD 2.5±0.7 93±1.7 53±34 85±11 81±18
p value 0.64 0.31 0.23 0.25
Abbreviations: A: asymmetric field arrangement; S: symmetric field arrangement; RICV: Radiation-
induced cerebral vasculopathy (RICV); TOX: index case with RICV; PTV: planning target volume; 








 LETd PTV 
(keV/µm)
LETd Vascular R 
(keV/µm)
LETd Vascular L 
(keV/µm)
 Maximum Mean   Maximum Mean Maximum Mean
 A-TOX  A 5.5 2.9        4.7 2.9 7.9* 4.3*
 B-TOX  A 5.3 2.6       7.7* 3.7* 4.9 2.8
C  S 4.6 3 5.9 3.3 6 3.3
 D  A 5.1 3.1 7.1 3 7.4 3.7
 E  S 4 2.7 3.9 3.1 3.9 3.1
 F  S 4.4 2.9 4.3 3.1 4.7 3.1
 G  S 4.2 3.1 4.5 3.1 4.6 3.2
 H  S 4.1 3.1 5.5 3.5 5.5 3.7
 I  S 4.1 3.2 4.1 3.1 4 3
 L  S 4.4 3.3 4.3 3.1 3.9 3.1
 M  S 4.3 3.1 4.3 3.1 3.9 2.4
 N  S 4.9 3 4.1 3.1 4.7 3.3
 O  S 4.1 3.3 4.2 3.2 4.1 3.2
 P  S 4.4 2.9 4.1 3 4.1 3.1
 Q  S 4.5 2.6 3.9 2.5 2.7 2.3
 R  S 4.2 3.4 5 3.1 4.9 3.4
LETd  values PTV                       Vascular structures
(keV/µm) Maximum  Mean Maximum     Mean 
mean ± SD 4.5±0.5 3.0±0.2 4.8±1.2       3.2±0.4
mean (RICV) ± SD 5.4±0.1 2.8±0.2 7.8±0.1    4.0±0.4
mean (non RICV) ± SD 4.4±0.3 3.1±0.2 4.6±1.0    3.1±0.3
p value 0.02 0.09  0.02  0.02
mean (A) ± SD      5.3±0.2 2.9±0.3 6.5±1.3    3.4±0.5
mean (S) ± SD      4.3±0.3 3.0±0.2 4.3±0.6    3.1±0.3
p value      0.01  0.12 0.002    0.65
Abbreviations: LETd: dose averaged Linear Energy Transfer; RICV: Radiation-induced cerebral 




- Vascular toxicity in craniopharyngioma pediatric cases after proton therapy was evaluated 
considering dosimetry and LET
- Two cases out of 16 pediatric patients presented with RICV. 
- Vascular toxicity was found only for patients treated with asymmetric field arrangements
- High max and average LET values were found for vascular toxicity areas identified on MRI for 
patients with RICV.  
